Literature DB >> 8322081

Carisoprodol (Soma): a new and cautious perspective on an old agent.

R A Littrell1, L R Hayes, V Stillner.   

Abstract

Carisoprodol (Soma, others) is a commonly prescribed, noncontrolled, skeletal muscle relaxant whose active metabolite is meprobamate. Patients for whom carisoprodol is prescribed are at risk for meprobamate dependence; several such cases have been reported. Toxicity and withdrawal associated with the use of meprobamate is high and has led to abandonment of this agent in clinical practice. Because carisoprodol possesses the same risks it should be avoided when possible, and it should be given schedule IV controlled substance status.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322081     DOI: 10.1097/00007611-199307000-00006

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  13 in total

1.  Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.

Authors:  Manish Kumar; Glenn H Dillon
Journal:  Eur J Pharmacol       Date:  2016-02-09       Impact factor: 4.432

2.  Assessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors.

Authors:  Manoj Kumar; Lorie A González; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2015-04-18       Impact factor: 5.250

3.  The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Margaretha Gulliksen; Harald Breilid; Vidar M Steen; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2005-07-15       Impact factor: 2.953

4.  Abuse Potential of Soma: the GABA(A) Receptor as a Target.

Authors:  Lorie A Gonzalez; Michael B Gatch; Michael J Forster; Glenn H Dillon
Journal:  Mol Cell Pharmacol       Date:  2009-01-01

5.  Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

Authors:  Gunchan Paul; Gautam L Parshotam; Rajneesh Garg
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2016 Jul-Sep

Review 6.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

7.  Carisoprodol abuse in Texas, 1998-2003.

Authors:  Mathias B Forrester
Journal:  J Med Toxicol       Date:  2006-03

8.  Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.

Authors:  Lorie A Gonzalez; Michael B Gatch; Cynthia M Taylor; Cathy L Bell-Horner; Michael J Forster; Glenn H Dillon
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

Review 9.  Muscle relaxants for non-specific low back pain.

Authors:  M W van Tulder; T Touray; A D Furlan; S Solway; L M Bouter
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Carisoprodol withdrawal induced delirium: A case study.

Authors:  Karen Ni; Margaret Cary; Paul Zarkowski
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.